TTC39B Inhibitors
TTC39B inhibitors encompass a diverse range of compounds that influence various biochemical pathways, ultimately leading to the inhibition of TTC39B's function in lipid metabolism. Specific inhibitors target the PPAR receptors, known to regulate fatty acid storage and glucose metabolism, which when inhibited, can decrease the expression of TTC39B. Other molecules act on the MAPK/ERK and PI3K/AKT signaling pathways, essential for cell proliferation, differentiation, and metabolism. The suppression of these pathways can indirectly reduce TTC39B levels, given its role downstream. Additionally, mTOR inhibitors exert their effects by suppressing protein synthesis and cell growth, consequently affecting TTC39B. This is particularly relevant as TTC39B is implicated in the regulation of lipid metabolism and autophagy, processes that are profoundly influenced by mTOR activity.
Further, compounds that inhibit cholesterol biosynthesis or transport, such as HMG-CoA reductase inhibitors and cholesterol transport inhibitors, can modulate TTC39B activity by altering cholesterol homeostasis and metabolism. Inhibition of long-chain acyl-CoA synthetase results in reduced acyl-CoA availability, which can subsequently decrease TTC39B activity due to its association with cholesterol metabolism. Additionally, agents that stimulate fatty acid oxidation may alsoreduce TTC39B expression by shifting the metabolic balance. Sirtuin inhibitors impact the regulation of metabolic and stress responses, therefore influencing TTC39B expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
A selective PPARγ antagonist that inhibits the activity of PPARγ receptors which are known to regulate fatty acid storage and glucose metabolism, thus potentially reducing the expression of TTC39B that is involved in lipid metabolism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which blocks the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation. Inhibition here could lead to reduced expression of genes like TTC39B that may be downstream in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress protein synthesis and cell growth by inhibiting the mTORC1 complex, potentially leading to reduced TTC39B levels as mTOR is involved in the regulation of lipid metabolism and autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that disrupts the PI3K/AKT signaling pathway, which is important for many cellular processes, including metabolism. Disruption of this pathway could indirectly lead to decreased function of TTC39B. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $27.00 $2809.00 $129.00 $210.00 $583.00 $88.00 | 11 | |
As an essential component of mammalian cell membranes and a substrate for biosynthesis of steroid hormones, bile acids, and vitamin D, excessive levels can lead to feedback inhibition mechanisms that might downregulate TTC39B expression. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
An inhibitor of long-chain acyl-CoA synthetase, which can reduce the availability of acyl-CoA for lipid synthesis. Since TTC39B is associated with cholesterol metabolism, its activity could be indirectly inhibited by such a blockade. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
A cholesterol transport inhibitor that disrupts intracellular cholesterol trafficking and can induce a phenotype resembling Niemann-Pick type C disease, potentially affecting TTC39B related pathways due to altered cholesterol homeostasis. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
An HMG-CoA reductase inhibitor that lowers cholesterol biosynthesis. It may indirectly affect TTC39B expression by modulating cholesterol levels and homeostasis, as TTC39B is implicated in cholesterol metabolism. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
This compound inhibits HMG-CoA reductase, potentially decreasing TTC39B activity by altering cholesterol metabolism and reducing the substrate availability for processes in which TTC39B is involved. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
A PPARα agonist that stimulates fatty acid oxidation, potentially reducing the expression or activity of TTC39B by altering lipid metabolism pathways where TTC39B is involved. | ||||||